Literature DB >> 16422915

On-demand SSRI treatment of premature ejaculation: pharmacodynamic limitations for relevant ejaculation delay and consequent solutions.

Marcel D Waldinger1, Dave H Schweitzer, Berend Olivier.   

Abstract

INTRODUCTION: Recently, the idea has emerged that on-demand use of serotonin reuptake inhibitors (SSRIs), particularly short half-life, should be equally effective in delaying ejaculation as daily SSRI treatment of premature ejaculation. AIM: To provide evidence that SSRI-induced ejaculation delay is mainly dependent on pharmacodynamic properties of the drug and hardly on pharmacokinetic factors, and that combined SSRI administration with specific 5-hydroxytryptamine (5-HT) receptor antagonism leads acutely to stronger ejaculation delay than acute SSRI monoadministration.
METHODS: We performed a detailed analysis of serotonin neurotransmission and reviewed animal studies with 5-HT(1A) receptor antagonists. In addition, we critically reviewed existing on-demand SSRI treatments publications and the current debate on a definition of premature ejaculation. MAIN OUTCOME MEASURES: Intravaginal ejaculation latency time (IELT).
RESULTS: Acute SSRI administration leads to only a mild or no increase of 5-HT neurotransmission and concomitant stimulation of postsynaptic 5-HT receptors. Existing on-demand SSRI treatment studies suffer from methodological insufficiencies, and the reported high-fold increases of ejaculation time contradict with neuropharmacological insights from serotonin metabolism. Animal studies show that SSRI coadministration with 5-HT(1A) receptor antagonists significantly increases the ejaculation time acutely compared to acute SSRI monoadministration.
CONCLUSION: On-demand SSRI treatment has less ejaculation-delaying effects than daily SSRI treatment. SSRIs with a short half-life are likely leading to much less ejaculation delay than current registered SSRIs. Combined use of SSRIs with 5-HT(1A) receptor antagonists increases the likelihood of clinically relevant ejaculation delay after on-demand treatment. On-demand SSRIs with short half-life that insufficiently delay ejaculation in men with IELTs less than 1 minute should be called ejaculation-delaying drugs rather than drugs against premature ejaculation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16422915     DOI: 10.1111/j.1743-6109.2005.20112.x

Source DB:  PubMed          Journal:  J Sex Med        ISSN: 1743-6095            Impact factor:   3.802


  15 in total

1.  In vitro measurement of ejaculation latency time (ELT) and the effects of vardenafil on ELT on lifelong premature ejaculators: placebo-controlled, double-blind, cross-over laboratory setting.

Authors:  Ahmet Gökçe; Abdullah Demirtas; Fikret Halis; Oguz Ekmekcioglu
Journal:  Int Urol Nephrol       Date:  2010-02-20       Impact factor: 2.370

Review 2.  Lifelong premature ejaculation: definition, serotonergic neurotransmission and drug treatment.

Authors:  Marcel D Waldinger
Journal:  World J Urol       Date:  2005-06-02       Impact factor: 4.226

Review 3.  Premature ejaculation: definition and drug treatment.

Authors:  Marcel D Waldinger
Journal:  Drugs       Date:  2007       Impact factor: 9.546

4.  Premature ejaculation: definition and drug treatment.

Authors:  François Giuliano
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 5.  Current therapeutic strategies for premature ejaculation and future perspectives.

Authors:  Zhong-Cheng Xin; Yi-Chen Zhu; Yi-Ming Yuan; Wan-Shou Cui; Zhe Jin; Wei-Ren Li; Tao Liu
Journal:  Asian J Androl       Date:  2011-05-02       Impact factor: 3.285

6.  Animal models of premature and retarded ejaculation.

Authors:  Marcel D Waldinger; Berend Olivier
Journal:  World J Urol       Date:  2005-06-07       Impact factor: 4.226

Review 7.  Current and emerging treatment options for premature ejaculation.

Authors:  Murat Gul; Kadir Bocu; Ege Can Serefoglu
Journal:  Nat Rev Urol       Date:  2022-08-25       Impact factor: 16.430

Review 8.  Animal models in urological disease and sexual dysfunction.

Authors:  Gordon McMurray; James H Casey; Alasdair M Naylor
Journal:  Br J Pharmacol       Date:  2006-02       Impact factor: 8.739

9.  Pharmacokinetics, Tolerability and Pharmacogenetics of DA-8031 After Multiple Ascending Doses in Healthy Male Subjects.

Authors:  Sejung Hwang; Dae Young Lee; Joo-Youn Cho; Jae-Yong Chung; In-Jin Jang; Kyung-Sang Yu; SeungHwan Lee
Journal:  Drug Des Devel Ther       Date:  2021-06-01       Impact factor: 4.162

10.  Dapoxetine: an evidence-based review of its effectiveness in treatment of premature ejaculation.

Authors:  Ej McCarty; Ww Dinsmore
Journal:  Core Evid       Date:  2012-01-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.